If you’re attending #ASHG26, join us for our presentation on Oct 23 to learn how our ExpressCT™ liquid biopsy technology adds the power of gene expression to existing cfDNA data. More details at tinyurl.com/3nd6yjd2. #ASHG #oncology #biotech

Introducing ExpressCT Rewind™, a retrospective fragmentomics analysis. Take CGP data beyond mutation profiling to extract gene expression info and develop custom biomarkers pointing to potential oncology treatment benefit – no new samples needed. tinyurl.com/3s3cwbnf #biotech

Let’s connect at #AACR26 during one of our oral or poster presentations on Apr 19 and 21. Learn more about our exciting new fragmentomics-based liquid biopsy technology and view details on our presentations at tinyurl.com/sxk24hfa. @myriadgenetics @TwistBioscience @DiscLS

Don’t miss GeneCentric CEO Michael Milburn at #PMWC26 on Thurs., March 5, at 11:30am PT. Check out the full conference program at tinyurl.com/5n7r6a27, and meet with us to learn more about our LBx technology. @PMWCintl

Make plans to join GeneCentric CEO Michael Milburn at #PMWC26 for the Clinical Dx Showcase, Track S2, March 5, 2026, at 11:30am PT. Contact us today to set up a meeting to learn more about our new LBx technology at genecentric.com/contact/. @PMWCintl

Welcome Jonathan Fisher as our new VP Commercial Partnerships! He will spearhead our business growth strategy, with a focus on expanding diagnostic partnerships and biopharma alliance programs. Request a meeting in San Francisco, Jan. 12-15, at bit.ly/4cc7edA. #JPM2026

Meet with us during #JPM2026! Learn how our RNA-based technology & liquid biopsy platform detect and track the dynamic biological activity of a tumor to deliver more precise biomarkers to improve diagnosis, prognosis, and #oncology therapy selection. genecentric.com/contact/

See our RWE study with @TempusAI in JCO Precision Oncology validating the clinical utility of the PurIST® test to personalize 1L chemotherapy for pancreatic cancer and improve the odds of improved survival and/or better quality of life. More at bit.ly/46bx3YZ

Today we announced the initial closing of an $8M Series C. Funds will help launch GenomicsNext™, a first-of-its-kind liquid biopsy platform that measures gene expression and provides high-fidelity DNA variant detection from ctDNA in one sample. bit.ly/43PYXtN

GeneCentric’s EXpressCTˢᵐ liquid biopsy platform is now available to bring the value of tissue RNA expression to liquid biopsy and provide deeper insights beyond DNA mutations. Learn more at bit.ly/3YqDXG9 #biotech #pharmaceutical #oncology

Just published in @CCR_AACR- in the GARNER study, our FGFR-PRS identified over 2x as many patients with high-risk #bladdercancer who could potentially benefit from FGFR-targeted therapy compared to those with DNA alteration biomarkers. More at bit.ly/3BoqqqL #oncology

Our PurIST test has received a PLA code from the @AmerMedicalAssn and is commercially available under a collaboration agreement with @TempusAI. Together, we’re driving the science to tackle #pancreaticcancer. More at bit.ly/3SmuHQS. #oncology #biotech

Counting down to #ASCO24! GeneCentric has 2 presentations, including new clinical validation results in #HNSCC & findings that help select #bladdercancer candidates for anti-PD-(L)1 inhibition treatment. More at bit.ly/4bnESvX. #oncology @UTHSC

#DYK that #bladdercancer is the 6th most common #cancer in the US & 80K+ people will be diagnosed this year? We’re working to help personalize and optimize cancer treatment, so patients may achieve greater clinical benefit. bit.ly/3wms7Ta #PrecisionMed #UroOnc

If you missed us last week at #AACR24, you can view our posters featuring data on our PurIST diagnostic test for pancreatic cancer and new MSS predictive response signature for colorectal cancer treatment at bit.ly/48T1x25. #precisionmedicine #oncology

We’re looking forward to presenting at #AACR24. Visit our poster presentations featuring data on our PurIST diagnostic test for pancreatic cancer and new MSS predictive response signature for colorectal cancer. bit.ly/3TEesP5 #precisionmedicine #oncology

Heading to #TRICON next week in San Diego? We’d love to tell you more about our novel RNA-based diagnostics for #oncology. Contact us to schedule a meeting at bit.ly/4cc7edA. #precisionmedicine

That's a wrap on the 20th @ASCO Genitourinary Cancers Symposium! We enjoyed coming together with the scientific community to present data and talk about our novel approach to RNA-based signatures and diagnostic tests for #cancer. View our #GU24 posters at bit.ly/48T1x25

Excited to see growing interest in transcriptomics and be part of the discussion at #PMWC24 last week. We believe it will play a critical role in #oncology and join researchers, clinicians & healthcare innovators driving new approaches to #precisionmedicine. @PMWCintl

Join GeneCentric CEO Michael Milburn at #PMWC24 for “Advancing Precision Medicine with Novel RNA Companion Diagnostics” on Wed., Jan 24, at 11:45am PT. View the full conference program at bit.ly/48LCU70. @PMWCintl #precisionmedicine #oncology